Bi Ruomeng, Chen Li, Huang Mei, Qiao Zhi, Li Zhen, Fan Gaofeng, Wang Yu
Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200092, China.
School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189221. doi: 10.1016/j.bbcan.2024.189221. Epub 2024 Nov 19.
The utilization of PARP inhibitors (PARPis) has significantly improved the prognosis for ovarian cancer patients. However, as the use of PARPis increases, the issue of PARPi resistance has become more prominent. Prolonged usage of PARPis can lead to the development of resistance in ovarian cancer, often mediated by mechanisms such as homologous recombination (HR) recovery, ultimately resulting in cancer relapse. Overcoming PARPi resistance in ovarian cancer is a pressing concern, aiming to enhance the clinical benefits of PARPi treatment and delay disease recurrence. Here, we summarize the mechanisms underlying PARPi resistance, methods for analyzing resistance, and strategies for overcoming it. Our goal is to inspire the development of more cost-effective and convenient methods for analyzing resistance mechanisms, as well as safer and more effective strategies to overcome resistance. These advancements can contribute to developing personalized approaches for treating ovarian cancer.
聚（ADP - 核糖）聚合酶抑制剂（PARPis）的应用显著改善了卵巢癌患者的预后。然而，随着PARPis使用的增加，PARPi耐药问题变得更加突出。PARPis的长期使用可导致卵巢癌产生耐药性，这通常由同源重组（HR）恢复等机制介导，最终导致癌症复发。克服卵巢癌中的PARPi耐药是一个紧迫的问题，旨在提高PARPi治疗的临床益处并延缓疾病复发。在此，我们总结了PARPi耐药的潜在机制、耐药性分析方法以及克服耐药性的策略。我们的目标是推动开发更具成本效益和便捷的耐药机制分析方法，以及更安全有效的克服耐药性的策略。这些进展有助于开发个性化的卵巢癌治疗方法。
